GH Research PLC (NASDAQ:GHRS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS) have earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $34.1111.

A number of brokerages have commented on GHRS. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Royal Bank Of Canada increased their price target on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Guggenheim reiterated a “buy” rating and issued a $29.00 price target on shares of GH Research in a research report on Monday, January 5th. Citigroup restated a “market outperform” rating on shares of GH Research in a research report on Tuesday, January 6th. Finally, Wolfe Research set a $39.00 price objective on GH Research in a research note on Tuesday, January 6th.

GH Research Stock Performance

NASDAQ GHRS opened at $15.80 on Friday. The stock has a 50 day moving average price of $14.85 and a 200-day moving average price of $14.01. GH Research has a one year low of $7.98 and a one year high of $19.51. The company has a market capitalization of $822.07 million, a P/E ratio of -21.35 and a beta of 0.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GHRS. Lynx1 Capital Management LP raised its stake in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after acquiring an additional 1,854,238 shares during the period. RTW Investments LP grew its holdings in GH Research by 6.5% during the 4th quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock valued at $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in GH Research in the 4th quarter worth about $22,860,000. Millennium Management LLC raised its position in GH Research by 324.1% in the 3rd quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock worth $12,350,000 after purchasing an additional 659,957 shares during the period. Finally, Jefferies Financial Group Inc. lifted its stake in GH Research by 0.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock worth $9,046,000 after purchasing an additional 2,988 shares during the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.